Peter Libby: Exploring Inflammation in Atherosclerosis: Lessons and Therapeutic Implications
Peter Libby, Mallinckrodt Professor of Medicine and Cardiovascular Specialist at Harvard Medical School and Brigham and Womens Hospital, shared a post on LinkedIn:
“Oliver Soehnlein led our update on inflammation in atherosclerosis and the opportunities for novel therapies to quench the smoldering within the plaque and improve clinical outcomes. Table 1 features “Emerging preclinical interference strategies aimed at reducing atherosclerosis” and Figure 5 presents a “Timeline of major milestones of research connecting inflammation with atherosclerosis” which we hope ongoing studies and clinical trials will soon extend as we seek the “sweet spot” of calming inflammation while avoiding undue interference with host defenses or tumor surveillance. Libby and Soehnlein, Inflammation in atherosclerosis: Lessons and therapeutic implications, Immunity (2025),”
Title: Inflammation in atherosclerosis: Lessons and therapeutic implications
Authors: Peter Libby, Oliver Soehnlein
Read full article here.
Stay updated with Hemostasis Today.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis